|
1
|
Hauber HP, Foley SC and Hamid Q: Mucin
overproduction in chronic inflammatory lung disease. Can Respir J.
13:327–335. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Park HU, Kim JW, Kim GE, Bae HI, Crawley
SC, Yang SC, Gum JR Jr, Batra SK, Rousseau K, Swallow DM, et al:
Aberrant expression of MUC3 and MUC4 membrane-associated mucins and
sialyl Le(x) antigen in pancreatic intraepithelial neoplasia.
Pancreas. 26:e48–e54. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Singh AP, Chauhan SC, Bafna S, Johansson
SL, Smith LM, Moniaux N, Lin MF and Batra SK: Aberrant expression
of transmembrane mucins, MUC1 and MUC4, in human prostate
carcinomas. Prostate. 66:421–429. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Voynow JA and Rubin BK: Mucins, mucus, and
sputum. Chest. 135:505–512. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rachagani S, Torres MP, Moniaux N and
Batra SK: Current status of mucins in the diagnosis and therapy of
cancer. Biofactors. 35:509–527. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kaur S, Sharma N, Krishn SR, Lakshmanan I,
Rachagani S, Baine MJ, Smith LM, Lele SM, Sasson AR, Guha S, et al:
MUC4-mediated regulation of acute phase protein lipocalin 2 through
HER2/AKT/NF-κB signaling in pancreatic cancer. Clin Cancer Res.
20:688–700. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chaturvedi P, Singh AP, Moniaux N,
Senapati S, Chakraborty S, Meza JL and Batra SK: MUC4 mucin
potentiates pancreatic tumor cell proliferation, survival, and
invasive properties and interferes with its interaction to
extracellular matrix proteins. Mol Cancer Res. 5:309–320. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bafna S, Kaur S and Batra SK:
Membrane-bound mucins: The mechanistic basis for alterations in the
growth and survival of cancer cells. Oncogene. 29:2893–2904. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Inata J, Hattori N, Yokoyama A, Ohshimo S,
Doi M, Ishikawa N, Hamada H and Kohno N: Circulating KL-6/MUC1
mucin carrying sialyl Lewisa oligosaccharide is an
independent prognostic factor in patients with lung adenocarcinoma.
Int J Cancer. 120:2643–2649. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schroeder JA, Masri AA, Adriance MC,
Tessier JC, Kotlarczyk KL, Thompson MC and Gendler SJ: MUC1
overexpression results in mammary gland tumorigenesis and prolonged
alveolar differentiation. Oncogene. 23:5739–5747. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elazeez Abd TA, El-Balshy A-L, Khalil MM,
El-Tabye MM and Abdul-Halim H: Prognostic significance of P27 (Kip
1) and MUC1 in papillary transitional cell carcinoma of the urinary
bladder. Urol Ann. 3:8–13. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patriarca C, Colombo P, Taronna Pio A,
Wesseling J, Franchi G, Guddo F, Naspro R, Macchi RM, Giunta P, Di
Pasquale M, et al: Cell discohesion and multifocality of carcinoma
in situ of the bladder: New insight from the adhesion molecule
profile (e-cadherin, Ep-CAM, and MUC1). Int J Surg Pathol.
17:99–106. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Du L, Qian X, Dai C, Wang L, Huang D, Wang
S and Shen X: Screening the molecular targets of ovarian cancer
based on bioinformatics analysis. Tumori. 101:384–389. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slichenmyer WJ and Fry DW: Anticancer
therapy targeting the erbB family of receptor tyrosine kinases.
Semin Oncol. 28 Suppl 16:S67–S79. 2001. View Article : Google Scholar
|
|
15
|
Schmidt M, Lewark B, Kohlschmidt N,
Glawatz C, Steiner E, Tanner B, Pilch H, Weikel W, Kölbl H and Lehr
HA: Long-term prognostic significance of HER-2/neu in
untreated node-negative breast cancer depends on the method of
testing. Breast Cancer Res. 7:R256–R266. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ross JS and Fletcher JA: The
HER-2/neu oncogene in breast cancer: Prognostic factor,
predictive factor, and target for therapy. Oncologist. 3:237–252.
1998.PubMed/NCBI
|
|
17
|
Ladjemi MZ, Jacot W, Chardès T, Pèlegrin A
and Navarro-Teulon I: Anti-HER2 vaccines: New prospects for breast
cancer therapy. Cancer Immunol Immunother. 59:1295–1312. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hynes NE and Stern DF: The biology of
erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta.
1198:165–184. 1994.PubMed/NCBI
|
|
19
|
Ponnusamy MP, Seshacharyulu P, Vaz A, Dey
P and Batra SK: MUC4 stabilizes HER2 expression and maintains the
cancer stem cell population in ovarian cancer cells. J Ovarian Res.
4:72011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ponnusamy MP, Singh AP, Jain M,
Chakraborty S, Moniaux N and Batra SK: MUC4 activates HER2
signalling and enhances the motility of human ovarian cancer cells.
Br J Cancer. 99:520–526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SH, Lee JH, Berek JS and Hu MC:
Auranofin displays anticancer activity against ovarian cancer cells
through FOXO3 activation independent of p53. Int J Oncol.
45:1691–1698. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu W, Li F, Mahavadi S and Murthy KS:
Upregulation of RGS4 expression by IL-1beta in colonic smooth
muscle is enhanced by ERK1/2 and p38 MAPK and inhibited by the
PI3K/Akt/GSK3beta pathway. Am J Physiol Cell Physiol.
296:C1310–C1320. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fu Z and Tindall DJ: FOXOs, cancer and
regulation of apoptosis. Oncogene. 27:2312–2319. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Banerjee S and Kaye SB: New strategies in
the treatment of ovarian cancer: Current clinical perspectives and
future potential. Clin Cancer Res. 19:961–968. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shigetomi H, Higashiura Y, Kajihara H and
Kobayashi H: Targeted molecular therapies for ovarian cancer: An
update and future perspectives (Review). Oncol Rep. 28:395–408.
2012.PubMed/NCBI
|
|
27
|
Singh AP, Moniaux N, Chauhan SC, Meza JL
and Batra SK: Inhibition of MUC4 expression suppresses
pancreatic tumor cell growth and metastasis. Cancer Res.
64:622–630. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carraway KL, Perez A, Idris N, Jepson S,
Arango M, Komatsu M, Haq B, Price-Schiavi SA, Zhang J and Carraway
CA: Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in
cancer and epithelia: To protect and to survive. Prog Nucleic Acid
Res Mol Biol. 71:149–185. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaturvedi P, Singh AP, Chakraborty S,
Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP
and Batra SK: MUC4 mucin interacts with and stabilizes the HER2
oncoprotein in human pancreatic cancer cells. Cancer Res.
68:2065–2070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ramsauer VP, Pino V, Farooq A, Carraway
Carothers CA, Salas PJ and Carraway KL: Muc4-ErbB2 complex
formation and signaling in polarized CACO-2 epithelial cells
indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol
Cell. 17:2931–2941. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Holbro T and Hynes NE: ErbB receptors:
Directing key signaling networks throughout life. Annu Rev
Pharmacol Toxicol. 44:195–217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Katoh M and Katoh M: Human FOX gene family
(Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
|
|
33
|
Alvarez B, Martínez-A C, Burgering BM and
Carrera AC: Forkhead transcription factors contribute to execution
of the mitotic programme in mammals. Nature. 413:744–747. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Furukawa-Hibi Y, Kobayashi Y, Chen C and
Motoyama N: FOXO transcription factors in cell-cycle regulation and
the response to oxidative stress. Antioxid Redox Signal. 7:752–760.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lu M, Zhao Y, Xu F, Wang Y, Xiang J and
Chen D: The expression and prognosis of FOXO3a and Skp2 in human
ovarian cancer. Med Oncol. 29:3409–3415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fei M, Zhao Y, Wang Y, Lu M, Cheng C,
Huang X, Zhang D, Lu J, He S and Shen A: Low expression of Foxo3a
is associated with poor prognosis in ovarian cancer patients.
Cancer Invest. 27:52–59. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Park SH, Chung YM, Ma J, Yang Q, Berek JS
and Hu MC: Pharmacological activation of FOXO3 suppresses
triple-negative breast cancer in vitro and in vivo. Oncotarget.
7:42110–42125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gandin V, Fernandes AP, Rigobello MP, Dani
B, Sorrentino F, Tisato F, Björnstedt M, Bindoli A, Sturaro A,
Rella R, et al: Cancer cell death induced by phosphine gold(I)
compounds targeting thioredoxin reductase. Biochem Pharmacol.
79:90–101. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Schuh E, Pflüger C, Citta A, Folda A,
Rigobello MP, Bindoli A, Casini A and Mohr F: Gold(I) carbene
complexes causing thioredoxin 1 and thioredoxin 2 oxidation as
potential anticancer agents. J Med Chem. 55:5518–5528. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pessetto ZY, Weir SJ, Sethi G, Broward MA
and Godwin AK: Drug repurposing for gastrointestinal stromal tumor.
Mol Cancer Ther. 12:1299–1309. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li H, Hu J, Wu S, Wang L, Cao X, Zhang X,
Dai B, Cao M, Shao R, Zhang R, et al: Auranofin-mediated inhibition
of PI3K/AKT/mTOR axis and anticancer activity in non-small cell
lung cancer cells. Oncotarget. 7:3548–3558. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tanaka H, Fujita N and Tsuruo T:
3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB
kinase beta (IkkB) phosphorylation activates NF-kappaB signaling. J
Biol Chem. 280:40965–40973. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee J, Bartholomeusz C, Mansour O,
Humphries J, Hortobagyi GN, Ordentlich P and Ueno NT: A class I
histone deacetylase inhibitor, entinostat, enhances lapatinib
efficacy in HER2-overexpressing breast cancer cells through
FOXO3-mediated Bim1 expression. Breast Cancer Res Treat.
146:259–272. 2014. View Article : Google Scholar : PubMed/NCBI
|
